Many supplements are available to the general public for a limited time on our SuppleNet page.
VOLUME 60 1999 SUPPLEMENT 10
Articles
3 Introduction. What Makes an Antipsychotic Atypical? Stephen M. Stahl, M.D., Ph.D.
[PDF]
5 Receptor Pharmacology of Neuroleptics:
Relation to Clinical Effects. Elliott Richelson, M.D.
[Abstract]
[PDF]
15 D2 and 5-HT2 Receptor Effects of Antipsychotics:
Bridging Basic and Clinical Findings Using PET. Gary Remington, M.D., Ph.D., F.R.C.P.C.,
and Shitij Kapur, M.D., Ph.D., F.R.C.P.C.
[Abstract]
[PDF]
20 Pharmacologic and Pharmacokinetic
Considerations in Choosing an Antipsychotic. Larry Ereshefsky, Pharm.D., F.C.C.P., B.C.C.P.
[Abstract]
[PDF]
31 Selecting an Atypical Antipsychotic by
Combining Clinical Experience With
Guidelines From Clinical Trials. Stephen M. Stahl, M.D., Ph.D.
[Abstract]
[PDF]
42 Does Loxapine Have “Atypical” Properties?
Clinical Evidence. William M. Glazer, M.D.
[Abstract]
[PDF]
47 Low-Dose Loxapine in the
Treatment of Schizophrenia: Is It More Effective
and More “Atypical” Than Standard-Dose Loxapine? Herbert Y. Meltzer, M.D., and Karuna Jayathilake, M.A.
[Abstract]
[PDF]
52 The Role of Typical and Atypical
Antipsychotic Medications in the
Management of Agitation and Aggression. Peter F. Buckley, M.D.
[Abstract]
[PDF]